Last reviewed · How we verify
Novel OPV2 candidate 1
At a glance
| Generic name | Novel OPV2 candidate 1 |
|---|---|
| Sponsor | Pierre Van Damme |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Novel OPV2 Vaccine (PHASE2)
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates (PHASE2)
- Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novel OPV2 candidate 1 CI brief — competitive landscape report
- Novel OPV2 candidate 1 updates RSS · CI watch RSS
- Pierre Van Damme portfolio CI